The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted Breakthrough ...
Blood-based Shield Multi-Cancer Detection (MCD) test exhibits high specificity, clinically meaningful sensitivity and strong cancer signal of origin accuracy Results informed National Cancer Institute ...
Hosted on MSN
Guardant Health (GH) partners with Manulife to launch Shield multi-cancer detection test in Asia
Guardant Health Inc. (NASDAQ:GH) is one of the most promising stocks under $100 to buy. On March 16, Guardant Health announced the launch of its Shield multi-cancer detection/MCD test in several Asian ...
First insurer in Asia to bring the innovative blood-based multi‑cancer screening solution to Hong Kong, Singapore, and the Philippines HONG KONG, SINGAPORE, and MANILA, Philippines, March 16, 2026 ...
Partnership marks the first introduction of Shield™ multi-cancer detection test in the region with availability across Hong Kong, Singapore and the Philippines Eligible Manulife customers in Hong Kong ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of the Shield™ multi-cancer detection (MCD) laboratory developed test (LDT) in multiple markets in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results